Creative Enzymes, a global enzyme technology service provider, has launched an AI-integrated biocatalysis platform designed to significantly accelerate the development of enzyme catalysts, a critical constraint in biomanufacturing. The platform, announced June 30, 2026, merges computational enzyme engineering with hands-on process development to deliver AI-driven biocatalysis solutions that are both predictable in silico and practical at industrial scale.
The platform addresses a persistent gap between identifying biocatalysis opportunities and having suitable enzymes available. Traditional development methods struggle to keep pace with iterative product development demands. By leveraging AI, Creative Enzymes aims to predict enzyme candidates for specific reactions, design enzymes constrained by process parameters, and anticipate process performance using key molecular features. This approach not only speeds development but also reduces R&D costs by minimizing the need to test numerous variants and lowers the risk of process failure.
The platform is structured into three specialized service modules. The first, AI-Driven Biocatalysis Solutions, provides an end-to-end workflow from target reaction analysis to scale-up characterization. It includes computational screening, process optimization, and scale-up evaluation, with quantitative data guiding decisions. For moderately complex targets, this reduces the conventional design-build-test-learn cycle from 12–24 months to 8–12 months. The second module, AI-Driven Industrial Biocatalysis, focuses on bridging lab performance and commercial production. It covers substrate concentration optimization, cofactor regeneration, immobilization, and integration of process analytical technology, delivering complete technology transfer packages. The third module, AI-Driven Green Biocatalysis, offers sustainability-focused solutions that align with corporate environmental goals. Enzymatic reactions in aqueous media at room temperature reduce solvent use and emissions, while enzymatic selectivity minimizes byproducts. AI-guided development amplifies these benefits by identifying more efficient enzymes.
Creative Enzymes demonstrated the platform's capabilities through a case study in transaminase engineering. Researchers developed a 6D protein engineering framework that combined interaction energy, solvent effects, and structural fragments to predict beneficial mutations. Five AI-selected transaminase variants, each with nine mutations, showed high solubility and catalytic stability at 7-liter fermentation scale. The engineered enzymes converted prochiral ketones to sitagliptin, achieving enantiomeric purity exceeding 99% and conversion rates up to 89% during scale-up.
The implications of this platform are broad. In pharmaceuticals, AI biocatalysis is already enabling asymmetric synthesis of chiral intermediates and replacing hazardous reagents. Agrochemicals and food industries are adopting it for fine-tuning toxicology profiles and delivering cleaner labels, while fine chemicals and personal care sectors explore high-value conversions and sustainable processes. By reducing development time and enhancing efficiency, Creative Enzymes' platform could accelerate the adoption of biocatalysis across multiple industries, driving more sustainable manufacturing.
